Cross Hepatotoxicity Between Tricyclic Antidepressants
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone -
Pharmacological Characterizations of H05, a Novel Potent Serotonin And
JPET/2018/248351 Title: Pharmacological characterization of (3-(benzo[d][1,3] dioxol-4-yloxy) -3-(4-fluorophenyl)-N, N-dimethylpropan-1-amine (H05), a novel serotonin and noradrenaline reuptake inhibitor with moderate 5-HT2A antagonist activity for the treatment of depression Authors: Xiangqing Xu, Yaqin Wei, Qiang Guo, Song Zhao, Zhiqiang Liu, Ting Xiao, Yani Liu, Yinli Qiu, Yuanyuan Hou, Guisen Zhang and KeWei Wang Affiliations: Department of Molecular and Cellular Pharmacology, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University , Beijing, China (X.X., T.X., K.W.W.); School of pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China (Y.W.); Institute of pharmaceutical research, Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou, Jiangsu, China (Q.G., S.Z., Z.L., Y.Q., Y.H., G.Z.); Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China (Y.L., K.W.W.) 1 Running title page Running title: A novel SNRI with 5-HT2A antagonist activity for treatment of depression Corresponding author: KeWei Wang Address: No. 38 Xueyuan Road, Haidian District, Beijing, 100191, China. Tel: 86•10•82805605; E•mail: [email protected] or [email protected] Number of text pages: 57 Number of tables: 3 Number of figures: 7 Number of references: 71 Words in Abstract: 248 Words in Introduction: 712 Words in Discussion:1357 Abbreviations: ADs: antidepressants; SSRIs: selective serotonin reuptake inhibitors; NRIs: norepinephrine reuptake inhibitors; SNRIs: serotonin and norepinephrine -
Current Topics in Behavioral Neurosciences
Current Topics in Behavioral Neurosciences Series Editors Mark A. Geyer, La Jolla, CA, USA Bart A. Ellenbroek, Wellington, New Zealand Charles A. Marsden, Nottingham, UK For further volumes: http://www.springer.com/series/7854 About this Series Current Topics in Behavioral Neurosciences provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats. With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The Behavioral Neurosciences series focuses on ‘‘translational medicine’’ and cutting-edge technologies. Preclinical and clinical trials for the development of new diagostics and therapeutics as well as prevention efforts are covered whenever possible. Cameron S. Carter • Jeffrey W. Dalley Editors Brain Imaging in Behavioral Neuroscience 123 Editors Cameron S. Carter Jeffrey W. Dalley Imaging Research Center Department of Experimental Psychology Center for Neuroscience University of Cambridge University of California at Davis Downing Site Sacramento, CA 95817 Cambridge CB2 3EB USA UK ISSN 1866-3370 ISSN 1866-3389 (electronic) ISBN 978-3-642-28710-7 ISBN 978-3-642-28711-4 (eBook) DOI 10.1007/978-3-642-28711-4 Springer Heidelberg New York Dordrecht London Library of Congress Control Number: 2012938202 Ó Springer-Verlag Berlin Heidelberg 2012 This work is subject to copyright. -
Antipsychotics
Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder and depression. This factsheet explains more about antipsychotic medication. There are two types of antipsychotics – ‘first generation’ or ‘typical’ (older medications) and ‘second generation’ or ‘atypical’ (newer medications). Antipsychotics affect people differently. If you take antipsychotics then you may get side effects. It can take some time to find the right medication. If you are taking an antipsychotic which you feel is not working, or if the side effects are difficult to live with, then you should discuss this with your GP or psychiatrist. You should not stop taking antipsychotics suddenly. Your antipsychotics can interact with other medications. It is important that your doctor is aware of all the medicine you are taking. This factsheet covers: 1. What are antipsychotics? 2. Are there different types of antipsychotics? 3. Are there any side effects? 4. What if I want to stop taking antipsychotics? 5. Do antipsychotics affect other medication? 6. Does alcohol affect my antipsychotics? 7. Can I drive when taking antipsychotics? 8. What else should I consider before taking antipsychotics? Top 1. What are antipsychotics? Psychosis is a medical term. If you have psychosis, you might see or hear things (hallucinations), or have ideas or beliefs that are not shared by other people around you (delusions). Some people describe it as a ‘break from reality’. Doctors may also describe it as ‘psychotic symptoms’, a ‘psychotic episode’ or a ‘psychotic experience’. -
Screening of 300 Drugs in Blood Utilizing Second Generation
Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone -
Lactose Intolerance and Health: Evidence Report/Technology Assessment, No
Evidence Report/Technology Assessment Number 192 Lactose Intolerance and Health Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA 290-2007-10064-I Prepared by: Minnesota Evidence-based Practice Center, Minneapolis, MN Investigators Timothy J. Wilt, M.D., M.P.H. Aasma Shaukat, M.D., M.P.H. Tatyana Shamliyan, M.D., M.S. Brent C. Taylor, Ph.D., M.P.H. Roderick MacDonald, M.S. James Tacklind, B.S. Indulis Rutks, B.S. Sarah Jane Schwarzenberg, M.D. Robert L. Kane, M.D. Michael Levitt, M.D. AHRQ Publication No. 10-E004 February 2010 This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10064-I). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. -
Review Article Monoamine Reuptake Inhibitors in Parkinson's Disease
Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review -
Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis
The Journal of Neuroscience, October 15, 2002, 22(20):8951–8960 Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis Kristin E. Larsen,1 Edward A. Fon,2 Teresa G. Hastings,3 Robert H. Edwards,4 and David Sulzer1 1Departments of Neurology and Psychiatry, Columbia University, and Department of Neuroscience, New York Psychiatric Institute, New York, New York 10032, 2Centre for Neuronal Survival, Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada, 3Departments of Neuroscience and Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, and 4Departments of Neurology and Physiology, University of California, San Francisco, California 94143 Methamphetamine (METH) selectively injures the neurites of pression. METH administration also promoted the synthesis of dopamine (DA) neurons, generally without inducing cell death. It DA via upregulation of tyrosine hydroxylase activity, resulting in has been proposed that METH-induced redistribution of DA an elevation of cytosolic DA even in the absence of vesicular from the vesicular storage pool to the cytoplasm, where DA can sequestration. Electron microscopy and fluorescent labeling oxidize to produce quinones and additional reactive oxygen confirmed that METH promoted the formation of autophagic species, may account for this selective neurotoxicity. To test granules, particularly in neuronal varicosities and, ultimately, this hypothesis, we used mice heterozygous (ϩ/Ϫ) or homozy- within cell bodies of dopaminergic neurons. Therefore, we pro- gous (Ϫ/Ϫ) for the brain vesicular monoamine uptake trans- pose that METH neurotoxicity results from the induction of a porter VMAT2, which mediates the accumulation of cytosolic specific cellular pathway that is activated when DA cannot be DA into synaptic vesicles. -
The Effect of the Process Variables on the HPLC Separation of Tricyclic Neuroleptics on a Calixarene-Bonded Stationary Phase
ORIGINAL ARTICLES Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany The effect of the process variables on the HPLC separation of tricyclic neuroleptics on a calixarene-bonded stationary phase H. Hashem, Th. Jira Received March 15, 2004, accepted May 25, 2004 Priv.-Doz. Dr. Thomas Jira, Ernst-Moritz-Arndt-University Greifswald, Institute of Pharmacy, Pharmaceu- tical/Medicinal Chemistry, F.-L.-Jahnstr. 17, D-17487 Greifswald, Germany [email protected] Pharmazie 60: 186–192 (2005) The chromatographic behavior of a new HPLC-stationary phase with supramolecular selectors on the basis of calixarenes is described for the separation of nine tricyclic neuroleptics. The effects of differ- ent chromatographic conditions (buffer system, pH-value, type and content of organic modifier, injec- tion volume) on the separation of the analytes were studied. Additionally, the effect of structural differ- ences of the neuroleptic analytes was studied. The chemical structure and pKa of the neuroleptics highly influenced their separation on the calix[8]arene phase. The separation of all analytes on the investigated calixarene-bonded stationary phase was possible with a mobile phase of acetonitrile with 30 mM ammonium acetate buffer (pH 3.5) 30 : 70(v/v) using 1 ml/min flow rate. 1. Introduction Neuroleptics which are widely used for the treatment of CH3 psychological problems are basic compounds, mainly thiox- CH3 anthene and phenothiazine derivatives. Many papers de- N N CH3 scribe the separation of this pharmacological group of ana- N N CH3 lytes on the usual RP-stationary phases (Goldstein and Van S CH3 S O Vunakis 1981; Kountourellis and Markopoulou 1991; Trac- CH3 qui et al. -
(12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'. -
Antipsychotics-2020.Pdf
© Mind 2020 Antipsychotics Explains what antipsychotics are used for, how the medication works, possible side effects and information about withdrawal. If you require this information in Word document format for compatibility with screen readers, please email: [email protected] Contents What are antipsychotics? ...................................................................................................................... 2 Could antipsychotics help me? .............................................................................................................. 5 How to take antipsychotics safely ......................................................................................................... 9 What dosage of antipsychotics should I be on? .................................................................................. 15 Antipsychotics during pregnancy and breastfeeding ........................................................................... 17 What side effects can antipsychotics cause? ....................................................................................... 20 What is a depot injection? ................................................................................................................... 30 How can I compare different antipsychotics? ..................................................................................... 31 Can I come off antipsychotics? ............................................................................................................ 41 Alternatives to antipsychotics